BioSpace News Archive

Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, announced the results of a new study presented as a “Hot Topics” poster at the Society for Neuroscience conference

Recently completed Phase 3 RAMSES study confirms safety profile of AR101 in peanut-allergic children and teens

295 Regenerative Medicine Clinical Trials Now Supported by Cryoport; 38 Programs in Phase III

Quarterly GAAP revenues of $32.4 million and net loss attributable to Intrexon of $57.3 million including non-cash charges of $38.7 million

Today at the 28th Diabetes Technology Meeting (DTM), Ascensia Diabetes Care has for the first time presented clinical research demonstrating that use of the CONTOUR®DIABETES app can reduce the chances of hypoglycemic and hyperglycemic events in people with diabetes.

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback

Advanced Key Initiatives for NDA Submission

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the third quarter 2018.

Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, today announced its financial results for the third quarter ended September 30, 2018.

BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today reported new data from its clinical program for Plinabulin, which demonstrated a superior immune profile compared to Neulasta (pegfilgrastim) based on promyelocytes and immature neutrophil data from clinical study.